The COVID-19 strain that has spread in the United Kingdom, now the dominant virus strain in the United States, is making the pandemic more difficult to control. But it also comes with a silver lining: the licensed vaccine will work well with it.
A variant, called B.1.1.7, can better take advantage of the lack of masking and social aloofness, and requires more people to develop the immune response to slow down a vaccine from Pfizer Inc. And its partners BioNTech SE, Moderna Inc. and Johnson & Johnson, along with precautionary measures, remain in effect, and the health agency said the footage had begun to slow down Covid-19 patients in the United States.
“If we didn’t have this vaccination background, we would have been horrible now,”; said Joshua Schiffer, associate professor in the Department of Vaccines and Infectious Diseases at the Fred Hutchinson Cancer Research Center. Much more difficult, ”he said.
The B.1.1.7 variant first appeared in the UK late last year, prompting another serious and stringent blockade. It has spread to several other countries, including the United States, which has quickly become the most common virus variant.Nearly 60% of Covid-19 cases in the United States could be due to this change by early April, according to the Control Center. And prevent disease
A study published in March in the journal Science suggested that B.1.1.7 ranged from 43% to 90% more infections than pre-existing variables. On average, each person can transmit the virus to more people, making the spread of the virus more severe.